our Premium Content: News alerts, weekly reports and conference planners

GENE:

FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

News alerts, weekly reports and conference planners

Interactions between circulating inflammatory factors and autism spectrum disorder: a bidirectional Mendelian randomization study in European population. (PubMed, Front Immunol)

This MR study identified additional inflammatory factors in patients with ASD relative to previous studies, and raised a possibility of ASD-caused immune abnormalities. These identified inflammatory factors may be potential biomarkers of immunologic dysfunction in ASD.

6 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • IL2 (Interleukin 2) • CD5 (CD5 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CASP8 (Caspase 8) • IL7 (Interleukin 7) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

16d

FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. (PubMed, Cell)

Thus, FLT3L is required for B cell and DC development in mice and humans. However, unlike its murine counterpart, human FLT3L is required for the development of monocytes but not NK cells.

16 days ago

Preclinical • Journal

FLT3 (Fms-related tyrosine kinase 3) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

18d

Injectable thermo-sensitive hydrogel enhances anti-tumor potency of engineered Lactococcus lactis by activating dendritic cells and effective memory T cells. (PubMed, Bioact Mater)

Besides, administration of FOLactis/P407 significantly inhibits the growth of abdominal metastatic tumors and orthotopic gastric tumors, resulting in an extended survival time. Therefore, these findings demonstrate the delivery approach of engineered bacteria based on in situ hydrogel will promote the efficacy and universality of therapeutics.

18 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

22d

Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. (PubMed, Cancer Genomics Proteomics)

Genes reported herein may be effective biomarkers to identify TNBC patients who will and will not benefit from immunotherapy and may be particularly important genes for developing future treatment strategies, including immunotherapy.

22 days ago

Journal • IO biomarker • Immune cell

IFNG (Interferon, gamma) • CA9 (Carbonic anhydrase 9) • CD3D (CD3d Molecule) • ENO1 (Enolase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • PRKCB (Protein Kinase C Beta) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • STAT4 (Signal Transducer And Activator Of Transcription 4) • ARHGAP30 (Rho GTPase Activating Protein 30)

CA9 expression

2ms

Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study. (PubMed, Int J Mol Sci)

We also examined the effects of I836 variants on binding affinity to sorafenib using molecular docking...Many single-nucleotide variations in FLT3 have an impact on its structure and function. Thus, the annotation of FLT3 SNVs and the prediction of their deleterious pathogenic impact will facilitate an insight into the tumorigenesis process and guide experimental studies and clinical implications.

2 months ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

FLT3 I836

sorafenib

3ms

Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication. (PubMed, Cell Mol Life Sci)

YAP inactivation in HCs and BECs causes liver damage, and concomitant TAZ deletion does not enhance but reduces this phenotype. Additionally, we present a new mechanism by which YAP contributes to cell-cell communication originating from NPCs.

3 months ago

Journal

ICAM1 (Intercellular adhesion molecule 1) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

4ms

BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer. (PubMed, J Cancer)

After surgery or reresection, chemotherapy drugs (epirubicin) or medications such as Bacillus Calmette-Guérin (BCG) are used for bladder instillation therapy, which can reduce the risk of bladder cancer recurrence and progression...In vitro experiments showed that FLT3LG can synergize with T-cell receptor activators to promote the activation of tumor-derived T cells. This study partially elucidates the mechanism of CD8 T-cell activation in BCG immunotherapy and provides a theoretical basis for optimizing BCG instillation therapy in bladder cancer.

4 months ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

epirubicin

8ms

MIRACLE: MR Evidence of Cardiac Inflammation Post-Stroke (clinicaltrials.gov)

P=N/A, N=44, Recruiting, Lawson Health Research Institute | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024

8 months ago

Trial completion date • Trial primary completion date • MRI

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • FGF19 (Fibroblast growth factor 19) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CD5 (CD5 Molecule) • IL10 (Interleukin 10) • CCL19 (C-C Motif Chemokine Ligand 19) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CASP8 (Caspase 8) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • CCL8 (C-C Motif Chemokine Ligand 8) • FGF21 (Fibroblast Growth Factor 21) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • AXIN1 (Axin 1) • CD40 (CD40 Molecule) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL17C (Interleukin 17C) • MMP1 (Matrix metallopeptidase 1) • TNFSF10 (TNF Superfamily Member 10) • TSLP (Thymic Stromal Lymphopoietin) • CDCP1 (CUB Domain Containing Protein 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • IL33 (Interleukin 33) • PLAU (Plasminogen Activator) • S100A12 (S100 Calcium Binding Protein A12) • SULT1A1 (Sulfotransferase Family 1A Member 1) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B) • TNFSF11 (TNF Superfamily Member 11) • TNFSF14 (TNF Superfamily Member 14)

10ms

ICONIC: Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer (clinicaltrials.gov)

P2, N=100, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Aug 2030

10 months ago

Enrollment open • Trial completion date

FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

capecitabine • oxaliplatin • Enweida (envafolimab)

11ms

ICONIC: Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

11 months ago

New P2 trial

FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

capecitabine • oxaliplatin • Enweida (envafolimab)

11ms

RAIC: Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC (clinicaltrials.gov)

P2, N=38, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2023 --> Apr 2024

11 months ago

Trial primary completion date • Metastases

FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)

Tyvyt (sintilimab) • capecitabine • oxaliplatin

12ms

Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms. (PubMed, Endocr Relat Cancer)

Combining FLT3LG and T cell counts further improved this prediction. Therefore, tumor-infiltrating cDC and T cells are prognostic markers in NET G2/ G3 or NEC and FLT3LG mRNA may serve as a simple to use biomarker for a quantitative estimate of their abundance, mandating prospective evaluation in the context of immune-targeted therapies.

12 months ago

Retrospective data • Journal

FLT3 (Fms-related tyrosine kinase 3) • CDK1 (Cyclin-dependent kinase 1) • ITGAX (Integrin Subunit Alpha X) • CD1C (CD1c Molecule) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)